KFDA approves Exelon for treatment of dementia associated With Parkinson's disease

Published: 2006-09-15 06:56:00

Updated: 2006-09-15 06:56:00

Novartis Korea announced it has received from the Korea Food and Drug Administration an additional approval of Exelon (rivastigmine tartrate) for the treatment of mild to moderate dementia associated with Parkinson's disease.

The company said that Exelon is the first and only medication available for the treatment of dementia associated with Parkinson's disease. Exelon is currently approved ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.